Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (2368)	6/8/2009 3:33:47 PM
From: Jibacoa	Respond to of 3722

ARNA is up 22.84% with volume now > 13,512,300 which is >4x its ADV. <g> The stock has now fully closed its March 30 DG bigcharts.marketwatch.com ARNA is responding to the poster yesterday at the American Diabetes Association's 69th Scientific Sessions in New Orleans. <g> finance.yahoo.com It is also been helped by the fact that it was able to trim some its loss on the 1stQ on 2% better revenues. The EL for 2009 is around $1.70 vs. the $3.24 loss in 2008 and for 2010 a further trim of its loss to $1/shr is expected.<g> The next resistance is now the March 12 H at $5.57 before it can test the Feb 12 H at $7.42 <g> bigcharts.marketwatch.com The more important resistance at the $10 level seems too far away at present.<g> bigcharts.marketwatch.com Bernard

To: Mike McFarland who wrote (2368)	5/12/2010 11:19:52 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

EXEL was up 12.57% and is still up 10.69% at present with volume of >1.41M already close to its ADDV The stock opened with an UG but could not go over the resistance at the $6 level.<g> bigcharts.marketwatch.com EXEL reported its 1stQ results yesterday and ha a CC after the market closed. Revenues were 67% better, $42.2 vs.$25.3M and the loss was cut some from $0.34 to $0.29 <g> The increase increase in revenue was primarily due to revenue from XL147, XL765 and discovery PI3K collaborations with SNY also with DNA on XL518 relating to a $7M milestone payment in the Q. Cash and cash equivalents, marketable securities, long-term investments and restricted cash and investments totaled $168.5M at Mar31 vs. $221M in Dec31. They started a PIb/2 for XL147 in breast Ca and a PII for XL147 in endometrial Ca. They plan to make 12 presentations on their compounds at ASCO, which will highlight the potential of XL184 in medullary thyroid cancer, glioblastoma, and several additional tumor types. <g> The stock needs to get off from the DT coming from the Dec24 H at the $8 level before it can test the more important resistance at $12.77 from its Jun2007 H <g> bigcharts.marketwatch.com Bernard